… , and asthma symptom scores (p ≤ 0.001 each). In summary, infants and children with …
asthma can be effectively treated with once‐daily BIS. For children with more severe asthma…

… may help explain the varying efficacy of anticholinergic drugs in … or modified to enhance their
pharmacokinetics and thus improve … efficacy of corticosteroids in treating asthma, long-term …

… Following intravenous administration in a single ascending intravenous dose study (0.0003–3
mg/kg) in patients with mild atopic asthma, the pharmacokinetic activity was approximately …

… Perhaps the most likely explanation is that asthmatic patients developed a false sense of
security with the inhalers, and failed to seek appropriate medical care when they were critically …

… It is difficult to explain from the pharmacological point of view … of pharmacokinetic studies
has been performed in asthmatic … critical differences in the pharmacokinetic profile when the …

… -term treatment of asthma with ciclesonide at doses ranging 80–1,280 μg (ex-actuator) 82–88.
In summary, the pharmacokinetic and … exist in the pharmacokinetic and pharmacodynamic …

… Stereoselectivity in the pharmacokinetics of anti-asthma drugs may complicate the … of
the stereoselective pharmacokinetics and pharmacodynamics of chiral anti-asthma drugs …

… approved for the treatment of severe asthma. They have complex pharmacokinetic profiles.
… binding, as well as their glycosylation pattern, can influence the pharmacokinetics of mAbs. …

… pharmacokinetic characteristics of the three drug classes, the role of inhalers in influencing
their pharmacokinetic behavior, and the impact of severe asthma … The main explanation for …

… the feasibility of pharmacokinetic-pharmacodynamic … effect relationship with pharmacokinetic
dynamic modeling as … and the consequences for pharmacotherapy in bronchial asthma. …